SCHEMBL4091007

SCHEMBL4091007

COc1ccc2nc(-c3ccccc3Cl)nc(N3CCSCC3)c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.55
CYP1A2 P05177 5/20 0.52
CYP3A4 P08684 5/20 0.52
CYP2D6 P10635 4/20 0.52
MAPT P10636 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
CYP2C19 P33261 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
LMNA P02545 1/20 0.48
ABCG2 Q9UNQ0 1/20 0.46
TSHR P16473 3/20 0.45
USP2 O75604 2/20 0.45
MAPK1 P28482 2/20 0.45
CLK4 Q9HAZ1 2/20 0.45
SIRT1 Q96EB6 1/20 0.45
NTSR1 P30989 3/20 0.45
TP53 P04637 1/20 0.44
METAP1 P53582 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084996 0.90 ABCB1 (0.68) ABCB1CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL4098760 0.89 ABCB1 (0.67) ABCB1CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL4085214 0.88 CYP1A2 (0.59) ABCB1CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL4084947 0.87 ABCB1 (0.52) ABCB1CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL4090221 0.85 ABCB1 (0.60) ABCB1CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL4092285 0.83 ABCB1 (0.55) ABCB1CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL4084453 0.83 MEN1 (0.56) ABCB1CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL4091176 0.83 ABCB1 (0.78) ABCB1CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL4085061 0.81 MEN1 (0.53) ABCB1CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL1083927 0.77 MAPT (0.68) ABCB1CYP1A2CYP3A4CYP2D6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 ABCB1 2120/4885CYP1A2 2477/4885CYP3A4 2113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.